YD Bio Limited Lists on Nasdaq; Reports $0.42M Quarterly Revenue
1 report, 1 independent
Updated Sun 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
YD Bio Limited became listed on the Nasdaq exchange on September 27, 2026. The biotechnology company reported $0.42 million in revenue and $0.05 EPS for the quarter, which it released on September 1st. Equities researchers at Wall Street Zen subsequently upgraded the stock to a "hold" rating.
From dailypolitical.com
Why it matters
The listing provides public market access for YD Bio, a company specializing in DNA methylation-based cancer detection and ophthalmologic innovations. The reported quarterly revenue and analyst rating provide current metrics for investors tracking the biotechnology sector.
From dailypolitical.com
Who's involved
- NasdaqAmerican fully electronic stock exchange where YD Bio is listed
Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
Related events
- Advanced Biomed Inc. was listed on the Nasdaq exchange on September 4, 2026.
- HCW Biologics announced it is listed on the Nasdaq stock exchange.
- Generate Biomedicines Inc listed its shares on the Nasdaq stock exchange on August 25, 2026.
- Artelo Biosciences, Inc. listed its shares on the Nasdaq stock exchange on August 1, 2026.
- Connect Biopharma listed its stock on the Nasdaq exchange on August 1, 2026.